Cost-effectiveness of integrated collaborative care for comorbid major @entity308 in @entity1 with XXXX .

@entity1 @entity33679 @entity308 @entity5
OBJECTIVES: Comorbid major @entity308 is associated with reduced quality of life and greater use of healthcare resources. A recent randomised trial (SMaRT, Symptom Management Research Trials, Oncology-2) found that a collaborative care treatment programme ( @entity308 Care for @entity1 with @entity5 , @entity33679 ) was highly effective in treating @entity308 in @entity1 with @entity5 . This study aims to estimate the cost-effectiveness of @entity33679 compared with usual care from a health service perspective. METHODS: Costs were estimated using UK national unit cost estimates and health outcomes measured using quality-adjusted life-years (QALYs). Incremental cost-effectiveness of @entity33679 compared with usual care was calculated and scenario analyses performed to test alternative assumptions on costs and missing data. Uncertainty was characterised using cost-effectiveness acceptability curves. The probability of @entity33679 being cost-effective was determined using the UK National Institute for Health and Care Excellence's (NICE) cost-effectiveness threshold range of   20,000 to   30,000 per QALY gained. RESULTS: @entity33679 cost on average   631 more than usual care per @entity1 , and resulted in a mean gain of 0.066 QALYs, yielding an incremental cost-effectiveness ratio of   9549 per QALY. The probability of @entity33679 being cost-effective was 0.9 or greater at cost-effectiveness thresholds above   20,000 per QALY for the base case and scenario analyses. CONCLUSIONS: Compared with usual care, @entity33679 is likely to be cost-effective at the current thresholds used by NICE. This study adds to the weight of evidence that collaborative care treatment models are cost-effective for @entity308 , and provides new evidence regarding their use in specialist medical settings.
